

Câncer de Colo Uterino

Cisplatina + Radioterapia

Cisplatina: 40mg/m² IV D1 Semanal até
término da radioterapia Ref. (1)

Paclitaxel + Cisplatina

Paclitaxel: 135mg/m² IV D1 em infusão de 24 horas
Cisplatina: 75mg/m² IV D1 a cada 21 dias
Ref. (9)

Cisplatina + Topotecano

Cisplatina: 50mg/m² IV D1
Topotecano: 0,75mg/m²/dia IV D1 a D3 a cada 21 dias
Ref. (2)

Cisplatina + 5-Fluorouracil

Cisplatina: 75mg/m² IV D1
5-Fluorouracil: 1000mg/m² IV D1 a D5 a cada 21 dias
Ref. (3)

Cisplatina + Vinorelbina

Cisplatina: 80mg/m² IV D1
Vinorelbina: 25mg/m² IV D1, D8 a cada 21 dias
Ref. (4)

Cisplatina + Irinotecano

Cisplatina: 60mg/m² IV D1
Irinotecano: 60mg/m² IV D1, D8, D15
a cada 28 dias Ref. (5)

Docetaxel

Docetaxel: 100mg/m² IV D1 a cada 21 dias

Paclitaxel

Paclitaxel: 175mg/m² IV D1 a cada 21 dias
Ref. (6)

Irinotecano

Irinotecano: 125mg/m² IV D1, D8, D15, D22 com
folga de 14 dias Ref. (7)

Topotecano

Topotecano: 1,5mg/m²/dia IV D1 a D5 a cada 21 dias
Ref. (8)

Vinorelbina

Vinorelbina: 30 mg/m² IV semanalmente Ref. (10)

Ifosfamida

Ifosfamida: 1.200 mg/m² (com Mesna) IV D1 a D5 a cada 21 dias
Ref. (11)

Gencitabina

Gencitabina: 800 mg/m² IV D1, D8 e D15 a cada 28 dias
Ref. (12)

1. Rose, P.G., *et al.* Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. *N Engl J Med*, 1999. 340(15): p. 1144-53.
2. Long, H.J., 3rd, *et al.* Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. *J Clin Oncol*, 2005. 23(21): p. 4626-33.
3. Whitney, C.W., *et al.* Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. *J Clin Oncol*, 1999. 17(5): p. 1339-48.

4. Pignata, S., *et al.* Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. *J Clin Oncol*, 1999. 17(3): p. 756-60.
5. Chitapanarux, I., *et al.* Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. *Gynecol Oncol*, 2003. 89(3): p. 402-7.
6. Thigpen, T., *et al.* The role of paclitaxel in the management of patients with carcinoma of the cervix. *Semin Oncol*, 1997. 24(1 Suppl 2): p. S2-41-S2-46.
7. Verschraegen, C.F., *et al.* Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. *J Clin Oncol*, 1997. 15(2): p. 625-31.
8. Muderspach, L.I., *et al.* A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. *Gynecol Oncol*, 2001. 81(2): p. 213-5.
9. Piccart, M.J., *et al.* Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. *J Natl Cancer Inst*, 2000. 92(9): p. 699-708.
10. Morris M, Brader KR, Levenback C, *et al.* Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. *J Clin Oncol*. 1998; 16:1094-1098.
11. Sutton GP, Blessing JA, McGuire WP, *et al.* Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a gynecologic oncology group study. *Am J Obstet Gynecol*. 1993; 168:805-7.
12. Schilder RJ, Blessing JA, Morgan M, *et al.* Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group. *Gynecol Oncol* 76:204–207, 2000.